Details of the Drug

General Information of Drug (ID: DMFN07X)

• Drug Name: Nilutamide
• Synonyms: Anandron; Nilandron; Nilandrone; Nilutamida; Nilutamidum; Aventis Behring Brand of Nilutamide; Aventis Brand of Nilutamide; Hoechst Brand of Nilutamide; Nilutamida [Spanish]; Nilutamidum [Latin]; N 8534; RU 23908; Anandron (TN); RU 23908-10; RU-23908; Nilutamide (USAN/INN); Nilutamide [USAN:BAN:INN]; Nilutamide [USAN:INN:BAN]; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 317.22
  Logarithm of the Partition Coefficient (xlogp); 2
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 7
• ADMET Property:
  Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 38.0 - 59.1 hours [3]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 13.5098 micromolar/kg/day [4]
• Chemical Identifiers:
  Formula: C12H10F3N3O4
  IUPAC Name: 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
  Canonical SMILES: CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C
  InChI: InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)
  InChIKey: XWXYUMMDTVBTOU-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4493
  ChEBI ID: CHEBI:7573
  CAS Number: 63612-50-0
  DrugBank ID: DB00665
  TTD ID: D0SN9T
  INTEDE ID: DR1158
  ACDINA ID: D00469

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Antagonist	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[6]
NADPH-cytochrome P450 reductase (CPR)	DE3N2FM	NCPR_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Drug Response	[8]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[9]

Molecular Expression Atlas of This Drug

• The Studied Disease: Prostate cancer
• ICD Disease Classification: 2C82.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	1.00E-03	1.34E-01	1.10E+00
NADPH-cytochrome P450 reductase (CPR)	DME	POR	2.29E-03	2.74E-01	7.46E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nilutamide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Nilutamide caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[10]

Coadministration of a Drug Treating the Disease Different from Nilutamide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Nilutamide and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[11]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Ivosidenib.	Acute myeloid leukaemia [2A60]	[12]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Midostaurin.	Acute myeloid leukaemia [2A60]	[13]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Idarubicin.	Acute myeloid leukaemia [2A60]	[13]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Daunorubicin.	Acute myeloid leukaemia [2A60]	[13]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Nilutamide caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[13]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Gilteritinib.	Acute myeloid leukaemia [2A60]	[13]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Oliceridine.	Acute pain [MG31]	[13]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Nilutamide and Metronidazole.	Amoebiasis [1A36]	[11]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Ivabradine.	Angina pectoris [BA40]	[13]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Bepridil.	Angina pectoris [BA40]	[14]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Dronedarone.	Angina pectoris [BA40]	[14]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[15]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Cilostazol.	Arterial occlusive disease [BD40]	[13]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Posaconazole.	Aspergillosis [1F20]	[13]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Levalbuterol.	Asthma [CA23]	[16]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Terbutaline.	Asthma [CA23]	[17]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Pirbuterol.	Asthma [CA23]	[17]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Salbutamol.	Asthma [CA23]	[16]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Formoterol.	Asthma [CA23]	[17]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[13]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[13]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[13]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Nilutamide and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[14]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Telithromycin.	Bacterial infection [1A00-1C4Z]	[13]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Retigabine.	Behcet disease [4A62]	[13]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Nilutamide and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[19]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Loperamide.	Bowel habit change [ME05]	[20]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Lapatinib.	Breast cancer [2C60-2C6Y]	[13]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Tamoxifen.	Breast cancer [2C60-2C6Y]	[13]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Bosutinib.	Breast cancer [2C60-2C6Y]	[13]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[13]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[16]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Isoproterenol.	Conduction disorder [BC63]	[16]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Halothane.	Corneal disease [9A76-9A78]	[13]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Propofol.	Corneal disease [9A76-9A78]	[21]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Sevoflurane.	Corneal disease [9A76-9A78]	[13]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Probucol.	Coronary atherosclerosis [BA80]	[13]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Clofazimine.	Crohn disease [DD70]	[13]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Mifepristone.	Cushing syndrome [5A70]	[14]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Pasireotide.	Cushing syndrome [5A70]	[14]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Osilodrostat.	Cushing syndrome [5A70]	[13]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Nilutamide caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[22]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Sertraline.	Depression [6A70-6A7Z]	[13]
Trimipramine	DM1SC8M	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Trimipramine.	Depression [6A70-6A7Z]	[13]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Escitalopram.	Depression [6A70-6A7Z]	[14]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Clomipramine.	Depression [6A70-6A7Z]	[13]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Doxepin.	Depression [6A70-6A7Z]	[13]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Maprotiline.	Depression [6A70-6A7Z]	[13]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[13]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Deutetrabenazine.	Dystonic disorder [8A02]	[13]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Ingrezza.	Dystonic disorder [8A02]	[13]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Nilutamide and Cannabidiol.	Epileptic encephalopathy [8A62]	[13]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Pentamidine.	Fungal infection [1F29-1F2F]	[13]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Ketoconazole.	Fungal infection [1F29-1F2F]	[13]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[13]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Nilutamide and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[23]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Nilutamide and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[25]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Nilutamide and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[14]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Nilutamide and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[26]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[13]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Phenolphthalein.	Irritable bowel syndrome [DD91]	[14]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Crizotinib.	Lung cancer [2C25]	[27]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Ceritinib.	Lung cancer [2C25]	[14]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Osimertinib.	Lung cancer [2C25]	[28]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Selpercatinib.	Lung cancer [2C25]	[13]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Lumefantrine.	Malaria [1F40-1F45]	[11]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Halofantrine.	Malaria [1F40-1F45]	[29]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Hydroxychloroquine.	Malaria [1F40-1F45]	[13]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Primaquine.	Malaria [1F40-1F45]	[13]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[13]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Nilutamide and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[30]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Nilutamide and Idelalisib.	Mature B-cell leukaemia [2A82]	[31]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[32]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Vemurafenib.	Melanoma [2C30]	[14]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and LGX818.	Melanoma [2C30]	[13]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Panobinostat.	Multiple myeloma [2A83]	[33]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Thalidomide.	Multiple myeloma [2A83]	[11]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Siponimod.	Multiple sclerosis [8A40]	[11]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Fingolimod.	Multiple sclerosis [8A40]	[14]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Nilutamide and Ozanimod.	Multiple sclerosis [8A40]	[34]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Romidepsin.	Mycosis fungoides [2B01]	[13]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Nilotinib.	Myeloproliferative neoplasm [2A20]	[14]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Dasatinib.	Myeloproliferative neoplasm [2A20]	[13]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Promethazine.	Nausea/vomiting [MD90]	[13]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Granisetron.	Nausea/vomiting [MD90]	[13]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Dolasetron.	Nausea/vomiting [MD90]	[14]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Ondansetron.	Nausea/vomiting [MD90]	[13]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Entrectinib.	Non-small cell lung cancer [2C25]	[13]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Levomethadyl Acetate.	Opioid use disorder [6C43]	[13]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Lofexidine.	Opioid use disorder [6C43]	[13]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Rucaparib.	Ovarian cancer [2C73]	[13]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Buprenorphine.	Pain [MG30-MG3Z]	[13]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Triclabendazole.	Parasitic worm infestation [1F90]	[13]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Pimavanserin.	Parkinsonism [8A00]	[13]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Apomorphine.	Parkinsonism [8A00]	[13]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Famotidine.	Peptic ulcer [DA61]	[11]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[35]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Lefamulin.	Pneumonia [CA40]	[36]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Ritodrine.	Preterm labour/delivery [JB00]	[17]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Levomepromazine.	Psychotic disorder [6A20-6A25]	[13]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[37]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Nilutamide and Leflunomide.	Rheumatoid arthritis [FA20]	[14]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Quetiapine.	Schizophrenia [6A20]	[13]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Mesoridazine.	Schizophrenia [6A20]	[14]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Thioridazine.	Schizophrenia [6A20]	[14]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Aripiprazole.	Schizophrenia [6A20]	[11]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Iloperidone.	Schizophrenia [6A20]	[14]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Paliperidone.	Schizophrenia [6A20]	[13]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Perphenazine.	Schizophrenia [6A20]	[13]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Trifluoperazine.	Schizophrenia [6A20]	[13]
Risperidone	DMN6DXL	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Risperidone.	Schizophrenia [6A20]	[13]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Asenapine.	Schizophrenia [6A20]	[13]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Pimozide.	Schizophrenia [6A20]	[13]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Vardenafil.	Sexual dysfunction [HA00-HA01]	[13]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Nilutamide and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[13]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Nilutamide and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[14]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[14]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[13]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Pitolisant.	Somnolence [MG42]	[13]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[13]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Nilutamide and Naltrexone.	Substance abuse [6C40]	[38]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Lenvatinib.	Thyroid cancer [2D10]	[13]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Cabozantinib.	Thyroid cancer [2D10]	[13]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Papaverine.	Tonus and reflex abnormality [MB47]	[39]
Tizanidine	DMR2IQ4	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Tizanidine.	Tonus and reflex abnormality [MB47]	[13]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Tacrolimus.	Transplant rejection [NE84]	[13]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[13]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Nilutamide and Procainamide.	Ventricular tachyarrhythmia [BC71]	[14]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Propafenone.	Ventricular tachyarrhythmia [BC71]	[13]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Nilutamide and Flecainide.	Ventricular tachyarrhythmia [BC71]	[13]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Docusate sodium	E00563	23673837	Surfactant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Nilutamide 150 mg tablet	150 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2864).
• [2] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [3] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
• [6] Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica. 1991 Dec;21(12):1559-70.
• [7] Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
• [8] TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
• [9] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [10] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
• [11] Cerner Multum, Inc. "Australian Product Information.".
• [12] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [13] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [14] Canadian Pharmacists Association.
• [15] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [16] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [17] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [18] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [19] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [20] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [21] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [22] Cerner Multum, Inc. "Canadian Product Information.".
• [23] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [24] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [25] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [26] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [27] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [28] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [29] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [30] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [31] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [32] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [33] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [34] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [35] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [36] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [37] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [38] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [39] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]